Use of mono and di inositolphosphates for treating inflammation

• US 5,342,832 A
• Filed: 08/21/1992
• Issued: 08/30/1994
• Est. Priority Date: 12/21/1989
• Status: Expired due to Fees

• Current Assignee: Perstorp AB
• Original Assignee: Perstorp AB
• Inventors: Siren, Matti
• Primary Examiner(s): Hook, Gregory
• Application Number:
  US07/862,564
• Time in Patent Office: 739 Days
• Field of Search: 514/129, 514/109, 514/103
• US Class Current: 514/103
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

A method of preventing or alleviating tissue damage, diabetes and complications thereof, bone disorders, disorders related to transplantation, disorders related to abnormal levels of lipoproteins, cardiovascular disease and inflammatory disorders by providing a mammal having one or more of the above diseases with a preventing or an alleviating effective amount of a compound having the formula C₆ H₆ (OH)_6-n (OPO₃ H₂)_n, where n is an integer of 1 or 2.

Claims

1. A method of treating an inflammatory disorder in a human or an animal comprising administering to a human or an animal in need thereof an inflammatory disorder pharmaceutically effective amount of at least one isomer of an inositol monophosphate, inositol diphosphate or a salt thereof.

2. A method in accordance with claim 1 wherein said isomer is provided as a salt of an anion selected from the group consisting of sodium, potassium, calcium, magnesium, zinc and mixtures thereof.

3. A method in accordance with claim 1 wherein said inositol monophosphate or said inositol diphosphate is provided in a concentration in the range of between about 5% and about 95% by weight, based on the total weight of said pharmaceutically active ingredient.

4. A method in accordance with claim 2 wherein said salt is provided with a pharmaceutically acceptable carrier, excipient or additive.

5. A method in accordance with claim 4 wherein said salt and said pharmaceutically acceptable carrier, excipient or additive are provided in the form of tablets, granules or solutions.

6. A method in accordance with claim 1 wherein said isomer is selected from the group consisting of myo-inositol-monophosphate, myo-inositol-bisphosphate, epi-inositol-monophosphate, epi-inositol-bisphosphate, muco-inositol-monophosphate, muco-inositol-bisphosphate, neo-inositol-monophosphate, neo-inositol-bisphosphate, chiro-inositol-monophosphate, chiro-inositol-bisphosphate, allo-inositol-monophosphate, allo-inositol-bisphosphate, cis-inositol-monophosphate, cis-inositol-bisphosphate, scyllo-inositol-monophosphate and scyllo-inositol-bisphosphate.